SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
ADXN

Addex Therapeutics Ltd. (NASDAQ:ADXN)

CH · Delayed Price · Currency is USD
Healthcare · Biotechnology
$3.47+$0.07 (+2.06%)
 
Market cap
$4.27M
Insider Score
Health Score
Analyst consensus
Listed since
Feb 12, 2020
Market Cap$4.27M-52.5%
Revenue (ttm)$47.57K-48.1%
Net Income-$6.86M-13.5%
EPS-$5.60+25.8%
Shares Out1.23M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume18,218
Open$3.25
Previous Close$3.40
Day's Range$3.25 - $3.53
52-Week Range$2.56 - $10.43
Beta2.07
AnalystsBuy
Price Target$30.00(+764.55%)
Earnings Daten/a
+3.82% (1D)
No price history available.

About ADXN

Addex Therapeutics Ltd, a biopharmaceutical company in its development phase, specializes in the discovery, progression, and commercialization of small-molecule pharmaceutical products designed to address central nervous system (CNS) conditions. Based in Geneva, Switzerland, the firm's core research centers on identifying oral small molecule allosteric modulators that interact with G-protein coupled receptors. Its leading clinical programs feature Dipraglurant, intended for the treatment of levodopa-induced dyskinesia in Parkinson's disease and dystonia; ADX71149, targeting epilepsy and various other neurological disorders; and GABAB PAM, developed to combat addiction. Addex has established strategic licensing and collaborative partnerships with organizations including Janssen Pharmaceuticals Inc., Indivior PLC, and The Charcot–Marie–Tooth Association. Founded in 2002, the company changed its name from Addex Pharmaceuticals Ltd to its current designation in March 2012.

Address
Chemin des Mines, 9, Geneva, GE, 1202, CH
Market Cap
4 million
Employees
3
Industrial Classification
Biotechnology
Financial Health Score
Weak
From ADXN’s reported statements · Q2 2026 (trailing 12 months)
1 Day
+2.06%
5 Days
-6.22%
1 Month
+20.07%
6 Months
-49.19%
1 Year
-52.47%

$ADXN stock is featured in our Insider Trades datasets.

→ All Stock Lists

Recently reported changes in ADXN holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by ADXN's directors and management

Net Shares Purchased by Insiders−1−102025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

ADXN Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New ADXN patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to ADXN from public contracts

Source: USAspending.gov

Bull Case vs Bear Case

AI-generated from ADXN’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
No data yet
—
Analyst Ratings
No data yet
—
News & Sentiment
100% of score
72

News check: Addex's spinout Neurosterix successfully closed $105M Series B financing, demonstrating investor confidence and de-risking the pipeline.

Recent Insider Activity

Buys
0
Sells
0
Buy Value
$0
Distinct Buyers
0

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.